This post was originally published on here
Republish
Thank you for your interest in republishing! This HTML is pre-formatted to adhere to our guidelines, which include: Crediting both the author and Knowable Magazine; preserving all hyperlinks; including the canonical link to the original article in the article metadata. Article text (including the headline) may not be edited without prior permission from Knowable Magazine staff. Photographs and illustrations are not included in this license. Please see our full guidelines for more information.
Top science stories of 2025
In a year of funding chaos, ongoing climate change and pollution perils, we also saw the most powerful telescope yet, personalized gene therapy, and the next-best-thing to an HIV vaccine — not to mention a brand-new color
2025 was a year of turmoil for many scientists — particularly in the United States, where job cuts and budget slashing has left many reeling. But it was also a year of promising advances in fields from gene therapy to quantum computing.
In the US, executive orders by President Donald Trump led to the loss of thousands of jobs in government agencies, including NASA, which oversees space exploration, and NOAA, which runs the National Weather Service among other vital activities. Thousands of health-related research grants — especially those with any perceived link to diversity, equity and inclusion — were canceled or withheld. And Harvard and other universities saw billions of dollars held back, at least temporarily.
Trump’s budget proposal for 2026 (the US budget had not been finalized as Knowable Magazine went to press) features huge cuts to science funding, including slicing the budget for the National Science Foundation, the main granting agency for basic science research, in half. And cuts that have already been made spell bad news for global efforts to quash diseases and keep climate change in check.
Amid all the bad news, there have also been lives saved, technologies advanced and some very weird science conducted. Here are some of the things that captured Knowable’s attention in 2025.
Vaccine hits and misses
Public health faced big challenges this year. “There have been enormous changes in 2025, really driven by the current [US] administration and their attitude towards both foreign aid and domestic vaccine policy,” says epidemiologist William Moss at the Johns Hopkins Bloomberg School of Public Health and coauthor of an Annual Review of Public Health article on global vaccinations. The US withdrew from the World Health Organization (WHO) in 2025, for example, and said it would pull funding from Gavi, the Vaccine Alliance.
Experts are worried that increasing gaps in vaccination coverage will contribute to further outbreaks of infectious diseases previously thought to be under control. This year, for example, measles surged in North America: Canada lost its “measles elimination” status in November, with cases much higher than anything seen in decades, and the US may follow in 2026. Whooping cough is also on the rise.
Over the past 50 years, immunization has saved an estimated 154 million lives globally. Maintaining that is proving hard. The 2020 pandemic caused disruptions to vaccination campaigns, and many have not yet recovered to pre-pandemic levels. Part of the problem is growing anti-vax sentiments. In the United States, vaccine coverage in kindergartners has crept downward from around 95 percent to 92 percent over the past dozen years, with exemptions from one or more recommended vaccines reaching a record high of 3.6 percent in the 2024-25 school year. These trends could signal trouble ahead.
There is some good news. After three years of negotiation, delegates to the WHO (not including the US) adopted a Pandemic Agreement with a better system for equitably sharing vaccines and drugs. Coverage with the HPV (human papillomavirus) vaccine, which protects against the sexually transmitted virus that causes cervical cancer in women and some throat cancers in men, continues to increase. And despite the cancellation of $500 million in funding for messenger RNA (mRNA) research in the United States, researchers are increasingly enthusiastic about mRNA vaccines, following on their success during the Covid-19 pandemic. Early research suggests that mRNA vaccines could be particularly promising in the fight against cancer.
HIV hope — and setbacks
This year saw some good news on the HIV front. Experimental infusions of neutralizing antibodies allowed some people with HIV to achieve remissions lasting months or years without the usual daily doses of antiretroviral drugs. And in July, the WHO endorsed twice-a-year injections of a long-lasting, highly effective injectable drug called lenacapavir for HIV prevention, following on the heels of US approval for that use. Experts say this marks a momentous shift for people at risk of HIV. WHO Director-General Tedros Adhanom Ghebreyesus said: “While an HIV vaccine remains elusive, lenacapavir is the next best thing.”
These new treatments may be especially valuable given the Trump administration’s decision this year to dismantle programs run by the US Agency for International Development (USAID). This includes the disruptions to the President’s Emergency Plan for AIDS Relief (PEPFAR) that delivered a huge and shocking blow to the global HIV/AIDS effort this year. As a result, the United Nations effort UNAIDS — to which USAID used to be the largest donor — could be shuttered in 2026, four years ahead of schedule.
All this has left experts and advocates reeling, as the number of people living with HIV — still one of the world’s most deadly viruses — continues to climb. UNAIDS predicts that if the PEPFAR funds permanently disappear, there could be over 6 million additional HIV infections and an additional 4 million AIDS-related deaths by 2029. “The sudden withdrawal of lifesaving support is having a devastating impact,” said UNAIDS Executive Director Winnie Byanyima at a press briefing in March. “It is very serious.”
Spectacular space advances
Astronomers rejoiced as the new Vera C. Rubin Observatory, built atop a mountain in Chile, came online this year. The telescope hosts the world’s biggest camera, at 3.2 billion pixels, and is expected to gather more data in its first year than all previous optical telescopes combined. The project aims to catalog some 5 million asteroids, including 100,000 near-Earth objects, over the next decade. It will also help to study dark matter and objects such as supernovae, and pursue new discoveries, including optical signals of gravitational waves. “The Rubin Observatory promises to impact virtually every area of astronomy and astrophysics, often profoundly,” says astronomer Robert Kennicutt at the University of Arizona, coeditor of the Annual Review of Astronomy and Astrophysics.
Among the more unusual targets that Rubin will help to spot are interstellar objects — hunks of rock or ice blasting through our solar system from elsewhere. So far, astronomers have only detected three such objects, including 3I/ATLAS, which made its closest approach to Earth in December. It is suspected that there are many more to find; Rubin could spot dozens over the next decade.
Personalized gene editing gets started
Since the first gene therapy treatment based on CRISPR — which uses molecular scissors to precisely cut and modify DNA — was approved in 2023 for sickle cell disease, efforts to develop other treatments have ramped up. Therapies are under investigation for a host of conditions including type 1 diabetes, various cancers and even high cholesterol.
But the big headline this year was the first personalized gene therapy: A baby boy with a life-threatening genetic condition became the first to receive a customized therapy, using a CRISPR-based technique that can precisely edit individual DNA letters. Personalized CRISPR treatments could allow doctors to effectively treat people suffering from rare or even unique life-threatening conditions. Such diseases collectively affect hundreds of millions of people worldwide.
The team behind the baby boy’s successful procedure announced this October their intention to try similar treatments in more children starting in 2026, and in November the Food and Drug Administration launched a new pathway to market for these procedures. A Center for Pediatric CRISPR Cures in California was also created in July to help families facing ultra-rare diseases. Funded by the Chan Zuckerberg Initiative, the center will be led by researchers at UC Berkeley and UC San Francisco. “I know firsthand the heartbreak of telling parents that we don’t understand their child’s illness or that we don’t know how to treat them,” Priscilla Chan, pediatrician and co-CEO of the Chan Zuckerberg Initiative, said in a press release about the new center.
Hopes raised for more transplants
This year brought important progress for xenotransplantation, the practice of using donor organs from pigs or other animals for people who need transplants. While only a handful of people have so far received pig hearts or kidneys — in special cases where they had no other options — those cases are blazing a trail toward making this technique a clinical reality. “The numbers are small but mighty,” says Joseph Ladowski, a surgeon and researcher in transplant immunology at Duke University.
This year brought several experimental transplants of pig organs (including the first lung), with one pig kidney lasting nearly nine months, a new record, before failing. Most important, in February the FDA green-lit the first multiperson trials of pig kidney transplants, which will allow doctors to standardize and optimize the technique. We should see half a dozen more transplants of animal organs in 2026, says Ladowski, with numbers ramping up steeply after that.
Another exciting development happening in parallel may also help ease the global shortage of donor organs: using an enzyme to convert the blood type of donated organs, removing antigens that can result in rejection in both human and animal transplants. In October, a team reported the first transplant of a human kidney that had its blood type converted from type A to universal donor type O.
Potential treatment for Huntington’s disease
This year researchers reported a small but promising study in which they slowed the progression of Huntington’s disease, an inherited disorder that gradually breaks down neurons, causing uncontrollable movements and a progressive degradation of behavior and thought. The treatment, by the Amsterdam-based company uniQure, is the first to address the disease itself rather than simply easing its symptoms.
Researchers engineered a harmless virus to deliver small molecules called microRNAs designed to block the action of the defective gene that causes Huntington’s. Then they infused the virus into targeted regions of the brains of 29 patients. In those who got the higher of two doses, the treatment slowed the progression of the disease by 75 percent, the team found. The result is “a remarkable step forward for patients and families,” says Andreas Keller, a bioinformatician at Saarland University in Germany who studies potential clinical applications of microRNAs. “This is a convincing proof-of-concept.”
As the climate crisis deepens, renewables get energized
This year continued the growing momentum of the renewable energy transition, thanks in large part to the plummeting cost of solar power. According to an October report from the think tank Ember, the first half of 2025 saw renewable energy provide more than a third of global electricity, squeaking ahead of coal for the first time.
But that’s rare good news in a grim climate picture. US policy, notably, is generally moving against renewable energy: In a speech to the United Nations in September, President Donald Trump said “If you don’t get away from the green energy scam your country is going to fail.”
Worldwide efforts to fight climate change are seriously off target, according to the UN Environment Programme. Global emissions of carbon dioxide may have declined slightly in 2025, but they need to be falling much faster if we are to hit our climate targets. Experts now say we will miss the goal of limiting the warming to 1.5 degrees Celsius, but action can still help to stave off catastrophic consequences to ecology and humankind. “Every small fraction of a degree matters,” says Diana Ürge-Vorsatz, an environmental scientist and climate expert at Central European University and vice chair of the Intergovernmental Panel on Climate Change. The latest data put 2025 as the second- or third-hottest year on record, after record-breaking 2024, with an annual average temperature about 1.48 degrees Celsius above the pre-industrial average.
Porous metals come of age
A class of materials called metal organic frameworks (MOFs) hit the headlines this year with Nobel Prize recognition, along with the first signs of commercial applications. MOFs are the world’s most porous materials: crystals of metal ions linked by long organic molecules. Their porosity could make these molecular sponges useful as storage containers for gases or drugs.
“MOFs are very elegant, scientifically, and highly versatile,” says Ram Seshadri, a chemist and materials scientist at UC Santa Barbara and editor of the Annual Review of Materials Research.
Although they have been a scientific curiosity for decades, MOFs are now starting to gain traction in applications — in part because artificial intelligence has massively sped up the hunt for new MOF formulations with desired properties, and in part because of increased interest in sucking carbon dioxide out of the air to fight climate change. This May, a company launched a new factory for making MOF sponges to capture carbon dioxide from ambient air. Others are investigating using MOFs to harvest water from the air in desert regions, store hydrogen gas to use as a zero-carbon fuel, and even deliver drugs within the body.
Quantum computing gears up
Quantum computing made significant progress this year. Quantum computers are built from qubits, which exploit quantum behaviors to offer faster computation but are also inherently unstable and error prone. To make a practically useful quantum computer, designers have to create a multi-qubit system that produces a lower overall error rate than seen in the individual bits. There have been a few recent practical demonstrations of this “quantum error correction” process. And then in October, Google announced that its “quantum echoes” algorithm proved 13,000 times faster than a classical computer at predicting molecular structures — one of the first potentially practical applications.
That’s not the only quantum computing news this year. The 2025 Nobel Prize in physics went to some of the foundational research for quantum computing (fittingly, given that 2025 was also UNESCO’s International Year of Quantum Science and Technology). “Quantum computing is definitely accelerating,” says William Oliver, a quantum engineer at MIT. “It’s pretty exciting.”
Pollution perils stack up
The global effort to manage pollution faced big setbacks this year. In March, the US Environmental Protection Agency (EPA) announced more than 30 acts of deregulation, many aiming to remove controls it claims were “throttling” the oil and gas industries. In August, the EPA proposed rescinding its foundational 2009 Endangerment Finding, which concluded that greenhouse gas emissions are air pollutants that endanger public welfare. Rescinding the finding would eliminate the legal basis for the EPA’s climate-based regulations. A long list of rules being rolled back is being compiled by Harvard University’s environmental and energy law program, while the Natural Resources Defense Council is tracking canceled and frozen environmental funding.
On the international stage, a hoped-for treaty to end plastic pollution fell apart this summer as participants fought over the scope of what the treaty could reasonably cover and the strength of its promises. While negotiations are expected to resume at some point in the future, for now it is up to individual governments to set their own rules for reducing plastic pollution.
Meanwhile, controversial efforts to mine the ocean bottom for minerals took a step forward despite studies showing negative impacts of test mining on seafloor life. Mining in international waters falls under the purview of the International Seabed Authority, which is developing a Mining Code to regulate this activity. But in April, the Metals Company sidestepped this process by seeking a permit directly from the United States, which has not ratified the UN Convention on the Law of the Sea that governs the seabed authority. Trump issued an executive order in April to fast-track such mining applications. A final decision is still pending.
Mighty mitochondria: More than just powerhouses
The term “mitochondrial dysfunction” featured heavily in headlines this year as politicians and researchers alike leaned in to the idea that malfunctions of this subcellular structure may underlie chronic diseases ranging from Parkinson’s to cancer, diabetes and more. “It’s becoming more and more recognized that once you perturb mitochondria, a whole bunch of diseases can occur,” says Andrew Dillin, a molecular and cell biologist at the University of California, Berkeley.
Mitochondria, long called “the powerhouses of cells” because they convert nutrients into chemical fuel, turn out to do much more than that. In particular, these little structures inside our cells — which probably evolved from ancient bacteria — have retained their ancient abilities to communicate, making them a major hub for cell signaling and a big player in regulating stress, immunity and metabolism.
Work this year showed that they can, for example, act as a “watchtower” against bacterial infection, detecting invading pathogens and helping the immune system mount a response. Mitochondria seem to be critical for memory formation in immune T cells, have an unexpected role in tissue healing, and might be targeted to help us live healthier for longer in old age.
And finally …
A couple of fun science stories that captured the world’s attention early this year are worth noting, even though some observers have poured cold water on the findings.
In April, Texas-based Colossal Biosciences announced it had genetically re-created dire wolves, a large-bodied wolf species that last roamed North America more than 11,000 years ago. To be precise, the company made 20 genetic tweaks to 14 locations in the genome of gray wolves. Debate erupted about whether this really amounts to re-creating dire wolves, which are thought to differ from gray wolves by about 12 million letters of DNA. (Most experts say no.)
The work “marks a technical achievement in genome editing and synthetic embryology,” wrote stem cell biologist Dusko Ilic from King’s College London in a commentary. But, he adds, “what has been achieved is not resurrection, but simulation.” Work continues to “de-extinct” other animals, from the dodo to the woolly mammoth. Whether this is achievable or desirable is a matter of opinion. Other genetic techniques are also being used to try to save living species on the brink of extinction, such as the northern white rhino.
Another quirky headline-grabbing story came when scientists made people see a color no one had ever experienced before. Researchers used a laser to directly stimulate just one of the three types of color-sensitive cone cells in the retina: the M cone, which is most sensitive to medium-wavelength light. That never happens in the real world, because any light that stimulates the M cone would also stimulate the neighboring S (short) and L (long) cones to some degree. The five people who experienced this odd light show said the result looked “green-blue,” a color dubbed “olo” by the researchers. The work is a fun exploration of the weird and wonderful world of color perception.






